v3.26.3
STOCK-BASED COMPENSATION PLANS
12 Months Ended
Jun. 30, 2026
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION PLANS

NOTE 15 – STOCK-BASED COMPENSATION PLANS

 

The Company currently has one equity compensation plan, The InterGroup Corporation 2010 Omnibus Employee Incentive Plan (the “2010 Incentive Plan”). The plan has been approved by the Company’s stockholders. As of June 30, 2026 and 2025, there were no RSUs outstanding.

 

The InterGroup Corporation 2010 Omnibus Employee Incentive Plan

 

The 2010 Incentive Plan was approved by the Company’s shareholders on February 24, 2010 and authorizes up to 400,000 shares of common stock to be issued as equity compensation to officers and employees of the Company. The 2010 Incentive Plan provides for stock options, stock appreciation rights, performance awards and other stock-based compensation. Option awards are generally granted at an exercise price equal to the market price of the Company’s common stock on the grant date and vest based on continued service or other applicable vesting conditions. The 2010 Incentive Plan expires in February 2030. As of June 30, 2026 and 2025, approximately 114,000 and 14,000 shares, respectively, remained available for future grant under the 2010 Incentive Plan.

 

In March 2010, the Company granted 100,000 stock options at an exercise price of $10.30 per share. The options, which had been previously extended through March 16, 2026, expired unexercised on March 16, 2026.

 

In December 2013, the Company granted 133,195 non-qualified stock options at an exercise price of $18.65 per share. In December 2023, the expiration date of these options was extended from December 26, 2023 to December 26, 2029.

 

In March 2017, the Company granted 18,000 stock options at an exercise price of $27.30 per share. The options expire ten years from the grant date and were fully vested as of June 30, 2026.

 

In October 2023, the Company granted 18,000 stock options at an exercise price of $28.90 per share. The options expire ten years from the grant date and vest over three years, with 6,000 options vesting on each anniversary of the grant date.

 

During the years ended June 30, 2026 and 2025, the Company recorded stock option compensation expense of $44,000 and $105,000, respectively.

 

 

The following table summarizes stock option activity for the years ended June 30, 2026 and 2025:

 

 

          Weighted    Weighted     
      Number
of Options
  

Average

Exercise Price

  

Average

Remaining Life

  

Aggregate

Intrinsic Value

 
                    
Outstanding at  July 1, 2024   269,195   $16.81    4.15 years   $1,187,000 
Granted      -    -    -    - 
Exercised      -    -    -    - 
Expired      -    -    -    - 
Exchanged      -    -    -    - 
Outstanding at  June 30, 2025   269,195   $16.81    3.15 years   $125,000 
Exercisable at  June 30, 2025   257,195   $15.57    3.30 years   $125,000 
Vested and expected to vest at  June 30, 2025   269,195   $16.81    3.15 years   $125,000 
Outstanding at  July 1, 2025   269,195   $16.81    3.15 years   $125,000 
Granted      -    -    -    - 
Exercised      -    -    -    - 
Expired      100,000    10.30    -    - 
Exchanged      -    -    -    - 
Outstanding at  June 30, 2026   169,195   $20.66    3.60 years   $4,514,000 
Exercisable at  June 30, 2026   163,195   $20.36    3.73 years   $4,514,000 
Vested and expected to vest at  June 30, 2026   169,195   $20.66    3.60 years    $4,514,000 

 

Aggregate Intrinsic Value represents the amount by which the market price of the Company’s common stock exceeded the exercise price of in-the-money options at period end.

 

Unrecognized compensation cost related to unvested stock options outstanding at June 30, 2026 was not material and is expected to be recognized over the remaining requisite service period. Cash received from option exercises and the total intrinsic value of options exercised were $0 for each of the fiscal years ended June 30, 2026 and 2025. There were no stock options granted during fiscal 2026 or 2025.